High R&D and Outsourced Testing Costs Associated with New Pesticide Development and Expanded Applications
First written in FY2019. 5 of 8 entries say "Materialised", first in FY2020-Q1. Latest entry: FY2026.
Nippon Soda moved to the "Worse" side of this theme in 2019, 2 years before the typical company in this theme (2021).
The whole theme swung hardest in 2019: 5 of 14 companies on the "Worse" side.
0 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「Total research and development expenses were ¥7,098 million, equivalent to 4.7% of consolidated net sales.」
Research and development expenses increased from ¥6,422 million in the previous fiscal year to ¥7,098 million, while research and development expenses in the Agribusiness were ¥4,600 million. The cost burden associated with new agrochemical development and other activities was confirmed in the actual results. - FY2024WorsenedAnnual report
「In the Agribusiness, we expect to continue adjusting shipments in some regions to optimize distribution inventories, and research and development expenses to increase as the development of new agrochemicals progresses.」
The expected increase in research and development expenses related to new agrochemicals as development progresses was indicated again after a decline had been reported in the previous fiscal year. - FY2021-Q2MitigatedAnnual report
「In addition, research and development expenses and outsourced testing expenses associated with developing new agrochemicals declined.」
Research and development expenses and outsourced testing expenses associated with new agrochemical development, which had remained high and continued to increase since the previous fiscal year, declined during the cumulative second-quarter period. - FY2020MaterialisedAnnual report
「Although exports of the insecticide “Mospilan” grew, outsourced testing expenses associated with developing new agrochemicals and expanding the applications of existing products increased.」
The increase in outsourced testing expenses associated with new agrochemical development and expanded applications of existing products also occurred for the full year and became a factor behind lower operating income in the Agricultural Chemicals business. - FY2020-Q3MaterialisedAnnual report
「During the cumulative third-quarter period, net sales were ¥10,354 million, up 2.5% year on year, and operating income was ¥307 million, up 58.5%, due to firm export sales despite increased research and development expenses and outsourced testing expenses in the Agricultural Chemicals business, as well as increased plant construction projects in the Construction business.」
The increase in research and development expenses and outsourced testing expenses associated with new agrochemical development and expanded applications of existing products actually occurred in the third quarter as well. - FY2020-Q2MaterialisedAnnual report
「In the Agricultural Chemicals business, exports of the insecticide “Mospilan” increased, and the Plant Health business of Zoetis Japan K.K., acquired in the previous year, contributed to earnings through the insecticide “Glingard” and fungicide “Agrimycin.” However, exports of products including the fungicide “Topsin M” declined. Research and development expenses and outsourced testing expenses associated with developing new agrochemicals and expanding the applications of existing products also increased.」
The increase in research and development expenses and outsourced testing expenses associated with new agrochemical development and expanded applications of existing products continued, and the Agricultural Chemicals business posted an operating loss of ¥1,283 million. - FY2020-Q1MaterialisedAnnual report
「In the cumulative first quarter, the company began selling new products in the Chemicals Business and saw an increase in plant construction work in the Construction Business. However, due to higher raw material prices and increased R&D and contract testing expenses, sales were ¥33,083 million, up 2.3% year on year, and operating income was ¥982 million, down 40.6% year on year.」
The actual increase in research and development expenses and outsourced testing expenses associated with new agrochemical development and expanded applications of existing products, which had been expected to remain high in the previous fiscal year, emerged as a factor behind lower operating income. - FY2019First statedAnnual report
「Research and development expenses and outsourced testing expenses associated with developing new agrochemicals and expanding the applications of existing products are expected to remain high.」
The sustained high level of research and development expenses and outsourced testing expenses associated with new agrochemical development and expanded applications of existing products was first identified separately as a burden for the next fiscal year.